Sign In
Buy TAK
$17.09
-0.160 (-0.93%)
At Close: Jul 31, 2026
The collaboration combines Innovent's proven immuno-oncology ("IO") and antibody-drug conjugate ("ADC") R&D capability and Takeda's experience in global oncology drug development to accelerate Innove
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into a license and collaboration agreement with Innovent Biologics (HKEX: 01801) for th
US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership
05:03am, Tuesday, 14'th Oct 2025
U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda Pharmaceutical , deepening their use of artificial intelligence to accelera
Nabla Bio Signs Second Takeda Collaboration to Advance AI-Driven Design of Protein Therapeutics
05:00am, Tuesday, 14'th Oct 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nabla Bio, a biotechnology company pioneering de novo therapeutics design with generative AI, today announced a new, multi-year research collaboration with Takeda. U
Takeda Pharmaceutical to exit cell therapy research
09:41am, Wednesday, 01'st Oct 2025
Japanese drugmaker Takeda Pharmaceutical said on Wednesday it will discontinue its cell therapy research and look for a partner to advance candidates under development.
Bristol Myers, Takeda to pool data for AI-based drug discovery
05:31am, Wednesday, 01'st Oct 2025
Bristol Myers Squibb , Takeda Pharmaceuticals and Astex Pharmaceuticals are coming together to share proprietary data for training an artificial intelligence model to assist drug discovery and develop
Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually
05:40pm, Wednesday, 24'th Sep 2025
Takeda (TAK) offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31. TAK's pipeline includes first-in-class and best-in-class candidates, but
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE: TAK) today committed JPY 4.6 billion (approx. USD 32.1 million) to four new Global Corporate Social Responsibility (CSR) part
5 Best High-Yield Dividend Stocks to Buy Now
05:45am, Wednesday, 17'th Sep 2025
High-yield dividend stocks entice investors with payouts two to four times higher than the S&P 500's 1.4% average yield. But high yield often signals trouble -- sluggish growth, stretched payout ratio
Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran
08:00am, Tuesday, 16'th Sep 2025
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and VELA Transport today announced their business partnership, with Takeda set to become the first biopharmaceutical compan
Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit
08:45am, Thursday, 11'th Sep 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that Rhonda Pacheco, most recently group vice president of U.S. Cardiometabolic Health at Eli Lilly, will join Takeda, eff
RMX VAST™ Video Now Natively Supported in U.S. Government's TAK Platform
08:05am, Wednesday, 10'th Sep 2025
ST. LOUIS , Sept. 10, 2025 /PRNewswire/ -- RMX Industries, Inc. ("RMX" or the "Company") (OTCQB: RMXI), a leader in mission-critical video compression and tactical data solutions, today announced tha
Takeda Pharmaceutical Company Limited (TAK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
03:42am, Tuesday, 09'th Sep 2025
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 3:20 PM EDT Company Participants Milano Furuta - CFO & Director Conference C
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Oveporexton (TAK-861) Investor Call on Phase 3 Narcolepsy Type 1 Data Presented at World Sleep 2025 Company Participants Christopher David O'Reilly -
Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
03:00am, Monday, 08'th Sep 2025
SINGAPORE & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a
